Search Results

News < GPCRs in Oncology and Immunology Unbiased multitissue transcriptomic analysis reveals complex neuroendocrine and the hypothalamic‒pituitary‒adrenal (HPA) axis. and the HPA axis was explored by histology and multitissue transcriptomics, and the neuroendocrine-immune underlying SCI-IDS, this study assessed the differential regulation of the gene network associated with neuroendocrine , Neuroendocrine immunomodulatory axis , Neuroinflammation , SCI-induced immunodeficiency syndrome ,

Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine clinical characteristics of growth hormone (GH)-producing pituitary adenomas/somatotroph pituitary neuroendocrine

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing

GIPR, and somatostatin receptors in medullary thyroid carcinoma; and SSTRs, GLP1R, and GIPR in other neuroendocrine

Somatostatin receptors are clinically validated GPCR biomarkers for diagnosis and treatment of various neuroendocrine

These findings along with a shear-induced immunomodulatory secretome position elevated shear stress as

HCMV-created immunomodulatory mechanisms could be associated with the indirect effects.

virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling axis US28 expression increased the abundance of the key components of the S1P signaling axis, including an US28 also activated the S1P signaling axis in HCMV-infected cells.

substitutions and recurrent gene loss in sauropsids Published date October 14, 2024 Abstract "The CXCL16-CXCR6 axis This axis is linked to diseases like HIV/SIV, cancer, and COVID-19. Together, these highlight that the CXCL16-CXCR6 axis is pivotal in host immunity. Previous studies of the CXCL16-CXCR6 axis found genetic variation among species but were limited to primates

< GPCR News < GPCRs in Oncology and Immunology A GPCR-neuropeptide axis dampens hyperactive neutrophils Specifically, the Mrgpra1-NPFF axis counter-regulated interferon (IFN) γ-mediated neutrophil polarization

< GPCR News < GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction CD8-restricted Gαs-DREADD to activate CD8-restricted Gαs signaling and show that a Gαs-PKA signaling axis

< GPCR News < GPCRs in Oncology and Immunology The pyruvate-GPR31 axis promotes transepithelial dendrite

GPCRs in Oncology and Immunology From outside to inside and back again: the lysophosphatidic acid-CCN axis

< GPCR News < GPCRs in Oncology and Immunology A disturbed metabolite-GPCR axis is associated with microbial The aim of this study was to characterize the axis microbiota-metabolite-GPCR in intestinal surgical

The CCR6/CCL20 axis plays a fundamental role in immune homeostasis and activation. against CCR6 that could be a promising alternative to small molecules in the treatment of CCR6/CCL20 axis-related

GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis

One aspect of PDAC is elevated ATP levels, pointing to the purinergic axis as a potential attractive Mediated in part by highly druggable extracellular proteins, this axis plays essential roles in fibrosis

cisplatin-refractory ovarian cancer xenografts, demonstrating the therapeutic potential of targeting LPAR-UCA1-let-7 axis Thus, our results identify LPAR-UCA1-let-7 axis as a novel avenue for targeted treatment strategies."

Immunology GPR97 depletion aggravates imiquimod-induced psoriasis pathogenesis via amplifying IL-23/IL-17 axis

GPCRs drive the formation of actin-rich tunneling nanotubes in cancer cells via a Gβγ/PKCα/FARP1/Cdc42 axis

GPR37 to increase expression of the efferocytosis receptor Tim4 via an ERK-AP1-dependent signaling axis

The GPR176/GNAS complex inhibits mitophagy via the cAMP/PKA/BNIP3L axis, thereby promoting the tumorigenesis

Importantly, blocking the axis with an ADRA2A antagonist, yohimbine, disrupts tyramine-mediated suppression

apoptosis, inflammation, and osteogenic differentiation inhibition in hDPSCs via the miR-708-5p/GIT2 axis

predominant GPCR-mediated microbial metabolite-human cell interactions regulating gut-immune-brain axis

This regimen has long lasting side-effects, including neuroendocrine and cognitive problems, and ~ 30%